Jump to content
 







Main menu
   


Navigation  



Main page
Contents
Current events
Random article
About Wikipedia
Contact us
Donate
 




Contribute  



Help
Learn to edit
Community portal
Recent changes
Upload file
 








Search  

































Create account

Log in
 









Create account
 Log in
 




Pages for logged out editors learn more  



Contributions
Talk
 



















Contents

   



(Top)
 


1 See also  





2 References  














TKM-Ebola






Deutsch
Français
Galego

 

Edit links
 









Article
Talk
 

















Read
Edit
View history
 








Tools
   


Actions  



Read
Edit
View history
 




General  



What links here
Related changes
Upload file
Special pages
Permanent link
Page information
Cite this page
Get shortened URL
Download QR code
Wikidata item
 




Print/export  



Download as PDF
Printable version
 
















Appearance
   

 






From Wikipedia, the free encyclopedia
 


TKM-Ebola was an experimental antiviral drug for Ebola disease that was developed by Arbutus Biopharma (formerly Tekmira Pharmaceuticals Corp.)[1] in Vancouver, Canada.[2] The drug candidate was formerly known as Ebola-SNALP.[3]

TKM-Ebola is a combination of small interfering RNAs targeting three of the seven proteins in Ebola virus: Zaire Ebola L polymerase, Zaire Ebola membrane-associated protein (VP24), and Zaire Ebola polymerase complex protein (VP35).[2][3] By down-regulating these three proteins, TKM-Ebola inhibits virus replication and eliminates the infection. The drug was effective in rhesus monkeys infected with Ebola.[4] After the Ebola outbreak in West Africa in 2014, the new variant responsible for it was isolated from several Ebola virus families and the specific genomic sequence was determined. The company re-designed TKM-Ebola and renamed it as "TKM-Ebola-Guinea".[5]

In January 2014, Tekmira started a Phase I clinical trial of TKM-Ebola to assess its safety in healthy people with a dose of 0.24 mg/kg/day for seven day treatments. The FDA placed the trial on clinical hold in July 2014 to assess results, after some subjects had flu-like responses.[6] In August, the FDA changed the status to "partial hold", allowing the drug to be used under expanded access in people infected with Ebola but with the Phase I trial still suspended.[2] In April 2015 the FDA allowed the study to resume at a lower dose.[7]

A Phase II trial started on 11 March 2015 in Sierra Leone, West Africa and stopped enrolling new subjects on 19 June 2015 after it appeared not to work.[8][9] In July 2015 the company announced it was changing its name to Arbutus, suspending development of the drug for Ebola and changing its focus to developing treatments for hepatitis B virus.[10]

See also

[edit]

References

[edit]
  1. ^ "Tekmira Pharma is Now Arbutus Biopharma (ABUS)". Street Insider. 3 August 2015. Retrieved 16 May 2016.
  • ^ a b c David Kroll for Forbes. 7 August 2014 FDA Moves On Tekmira's Ebola Drug While Sarepta's Sits Unused
  • ^ a b "TKM-Ebola". BioCentury. BioCentury Publications Inc. Retrieved 1 August 2015.
  • ^ Thi, Emily P.; Mire, Chad E.; Lee, Amy C. H.; Geisbert, Joan B.; Zhou, Joy Z.; Agans, Krystle N.; Snead, Nicholas M.; Deer, Daniel J.; Barnard, Trisha R.; Fenton, Karla A.; MacLachlan, Ian; Geisbert, Thomas W. (22 April 2015). "Lipid nanoparticle siRNA treatment of Ebola-virus-Makona-infected nonhuman primates". Nature. 521 (7552): 362–65. Bibcode:2015Natur.521..362T. doi:10.1038/nature14442. PMC 4467030. PMID 25901685.
  • ^ "Tekmira Provides Periodic Update on TKM-Ebola Program (NASDAQ:ABUS)". investor.arbutusbio.com. Archived from the original on 8 December 2015. Retrieved 30 November 2015.
  • ^ Cynthia Koons, Caroline Chen and Robert Langreth for Bloomberg News. Aug 8, 2014 Ebola Drug by Tekmira May Be Used on Infected Patients
  • ^ "FDA modifies partial clinical hold on Tekmira Ebola study". Reuters. 10 April 2015. Retrieved 1 August 2015.
  • ^ Kupferschmidt, Kai (11 March 2015). "New Ebola drug trial starts in Sierra Leone". Science Magazine. AAAS. Retrieved 1 August 2015.
  • ^ Vogel, Gretchen; Kupferschmidt, Kai (19 June 2015). "In setback for potential Ebola drug, company halts trial". news.sciencemag.org. Retrieved 24 June 2015.
  • ^ Lisa Schnirring for CIDRAP News. Jul 20, 2015 Experimental Ebola drug shelved; study explores virus clearance

  • t
  • e

  • Retrieved from "https://en.wikipedia.org/w/index.php?title=TKM-Ebola&oldid=1186545887"

    Categories: 
    Antiviral drugs
    Ebola
    Abandoned drugs
    Immunology stubs
    Hidden categories: 
    Articles with short description
    Short description matches Wikidata
    Use dmy dates from April 2017
    All stub articles
     



    This page was last edited on 23 November 2023, at 22:51 (UTC).

    Text is available under the Creative Commons Attribution-ShareAlike License 4.0; additional terms may apply. By using this site, you agree to the Terms of Use and Privacy Policy. Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc., a non-profit organization.



    Privacy policy

    About Wikipedia

    Disclaimers

    Contact Wikipedia

    Code of Conduct

    Developers

    Statistics

    Cookie statement

    Mobile view



    Wikimedia Foundation
    Powered by MediaWiki